Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2276 participants.

Also called NCT04619927

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 2,276 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04619927
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Netherlands (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04619927. Randomized; no masking; primary purpose prevention. Start 2021-03-01 (actual); primary completion 2024-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease.
Acronym
GENPAD
Condition
Peripheral Arterial Disease
Intervention (Genetic)
Direct CYP2C19 genotyping
Intervention (Genetic)
CYP2C19 genotyping at the end of the study
Intervention (Drug)
Poor metabolisers
Intervention (Drug)
Intermediate metabolisers
Intervention (Drug)
Normal metabolisers and unknown metaboliser state
Lead sponsor
Radboud University Medical Center (class: other)
Collaborator
ZonMw: The Netherlands Organisation for Health Research and Development (class: other)
Collaborator
Academisch Ziekenhuis Groningen (class: other)
Collaborator
Rijnstate Hospital (class: other)
Collaborator
Bernhoven Hospital (class: other)
Collaborator
Canisius-Wilhelmina Hospital (class: other)

Record details

Record id
cardio:ct-nct04619927
Content hash
6951deb151b029208686b50060462f88c83ab8e292be4040a6631290a53fa989